Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-09-16

FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Accord Healthcare Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Accord Healthcare's levothyroxine sodium, a generic thyroid hormone replacement product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVOTHYROXINE SODIUM (levothyroxine sodium)

Snippet

SUPPL AP for LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)